Surmodics (NSDQ:SRDX) shares fell last week after the FDA wrote a letter to doctors detailing a trend of heightened mortality in people with peripheral artery disease who were treated with paclitaxel-coated devices.
In an SEC filing, the company said that it’s working with the FDA to clarify how the company should proceed with an ongoing clinical trial of its paclitaxel-coated SurVeil balloon.
Get the full story at our sister site, Drug Delivery Business News.
The post Surmodics shares down following FDA’s paclitaxel device update appeared first on MassDevice.
from MassDevice https://ift.tt/2Cpwyxu
Cap comentari:
Publica un comentari a l'entrada